Department of Gynecology and Obstetrics, University Hospital Basel, Spitalstrasse 21, CH-4031 Basel, Switzerland.
Eur J Surg Oncol. 2011 Jul;37(7):623-8. doi: 10.1016/j.ejso.2011.05.006. Epub 2011 May 31.
Contradictory data exists concerning the prognosis of patients with synchronous bilateral breast cancer (SBBC). Most authors report a worse prognosis for SBBC patients compared to unilateral breast cancer (UBC) patients. There are a few studies that did not support these findings. This study gives a comprehensive picture of SBBC and tests the hypothesis that outcome of this entity is based on the tumor with the worse prognosis (reference lesion).
PATIENTS & METHODS: The data of two prospective Swiss breast cancer databases covering a 20-year period (1990-2009) was reviewed. Forty-six cases of SBBC were identified. In 34 patients with early-stage SBBC, the reference lesions (defined as the tumor with the more advanced stage or, in cases where both tumors had the same stage, the larger tumor) were compared in a case-control approach with 100 patients having UBC (SBBC/UBC ratio = 1/3). The controls were matched for age, time of diagnosis, tumor size, axillary node status, histological grade and estrogen-receptor status. Differences in terms of survival curves were analyzed using the log rank test; the possible correlation between matched groups was evaluated by a frailty Cox model.
There were no significant differences in disease-specific survival between SBBC and its unilateral controls (HR, 0.932; 95% CI, 0.322-1.07; p = 0.90).
The prognosis of SBBC was determined by the reference lesion; the contralateral second tumor had no additional impact on outcome.
关于双侧同步性乳腺癌(SBBC)患者的预后存在相互矛盾的数据。大多数作者报告 SBBC 患者的预后比单侧乳腺癌(UBC)患者差。也有一些研究不支持这些发现。本研究全面描述了 SBBC,并检验了这样一个假设,即该疾病的结局是基于预后较差的肿瘤(参照病变)。
回顾了两个前瞻性瑞士乳腺癌数据库 20 年来(1990-2009 年)的数据。确定了 46 例 SBBC 病例。在 34 例早期 SBBC 患者中,采用病例对照方法,将参照病变(定义为分期较晚的肿瘤,或在两个肿瘤分期相同时,肿瘤较大者)与 100 例 UBC 患者(SBBC/UBC 比 = 1/3)进行比较。对照组在年龄、诊断时间、肿瘤大小、腋窝淋巴结状态、组织学分级和雌激素受体状态方面与患者相匹配。使用对数秩检验分析生存曲线差异;通过 frailty Cox 模型评估匹配组之间的可能相关性。
SBBC 与单侧对照之间在疾病特异性生存方面无显著差异(HR,0.932;95%CI,0.322-1.07;p=0.90)。
SBBC 的预后由参照病变决定;对侧第二肿瘤对结局没有额外影响。